| Pinnacle Pharmaceuticals, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110319367 | Phenazopyridine Compounds - The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine. | 12-29-2011 |
| 20110071108 | Beta-Cyclodextrin Derivatives as Antibacterial Agents - The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units. | 03-24-2011 |
| 20100204185 | PHENAZOPYRIDINE COMPOUNDS - The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine. | 08-12-2010 |
| 20090023210 | B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN - The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivatives displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity. | 01-22-2009 |
